课题基金 / 基金详情

BLR&D Research Career Scientist Award Application

BLR&D Research Career Scientist Award Application
BLR
批准号:
10293581
负责人:
Douglas L. Feinstein
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-10-01 至 2024-09-30
关键词:
AffectAfrican AmericanAfrican American populationAgeAgingAgonistAlcohol abuseAlcohol consumptionAlcoholsAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease riskAmyloidAmyloid beta-ProteinAnimal ModelAnticoagulantsAreaAwardBehaviorBlood specimenBrainCalciumCaucasiansCell Culture TechniquesCellsClinicClinicalClinical TrialsCognitive deficitsCraniocerebral TraumaDNADNA sequencingDepositionDevelopmentDevelopmental Therapeutics ProgramDiagnosisDietary FactorsDiseaseDown-RegulationEconomic BurdenEnvironmental Risk FactorEthanolExperimental Autoimmune EncephalomyelitisExposure toFDA approvedFamilyFrequenciesFundingGenesGeneticGoalsGrantHealthcare SystemsHeavy DrinkingHigh PrevalenceHispanicHumanIn VitroIncidenceInflammationInflammatory ResponseInterventionKnowledgeLAMC2 geneLesionMediatingMetforminMethodsMicrogliaMilitary PersonnelModelingMultiple SclerosisMyelin SheathNervous System TraumaNeurobiologyNeurodegenerative DisordersNeurogliaNeurologicNeuronsNeurosciencesNitric Oxide SynthaseNorepinephrineNucleotidesPaperPathologyPatientsPhagocytosisPharmaceutical PreparationsPilot ProjectsPioglitazonePopulationPost-Traumatic Stress DisordersProtein-Serine-Threonine KinasesProteinsRattusRelapsing-Remitting Multiple SclerosisResearchRiskRisk FactorsRodent ModelRodenticidesRoleSTK11 geneSamplingScientistSeminalSenile PlaquesServicesSeveritiesSiblingsSignal TransductionSingle Nucleotide PolymorphismSocietiesSupporting CellSymptomsSyndromeSystemT-LymphocyteTestingTimeToxic effectVariantVeteransWarfarinWomanWorkalcohol effectbasecareercohortcomorbiditydesigndisorder riskdrug repurposingdrug testinggenetic risk factorin vivointerestlocus ceruleus structuremilitary veteranmouse modelmultiple sclerosis patientneuroinflammationneuropathologynoradrenergicnovelphase I trialpilot testpreventrecruitreduce symptomsremyelinationsocialtherapy developmenttranscriptomeβ-amyloid burden

项目摘要

项目成果

Douglas L. Feinstein的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The major area of our research is to help understand the causes of, and development treatments for neurodegenerative diseases and conditions, in particular Alzheimer’s Disease (AD) and Multiple Sclerosis (MS). This work includes repurposing drugs that are FDA-approved for other indications but we show can provide benefit in animal models of AD and MS, making it easier to bring them to the clinic. A better understanding of how these diseases start and evolve, and identification of interventions will help reduce disease symptoms, as well as social and economic burdens. Our MS studies currently funded by a Merit grant have expanded into the area of genetic risk factors that may predispose one to developing MS, based on our findings of a novel nucleotide variant in one particular gene. We are now determining how the variant increases risk using cell cultures and a mouse model that we developed to replicate the human variant, and testing drugs to see if they can minimize its effects. We are also testing if this variant, or others, is present at higher frequency in certain veteran populations, including in African American, Hispanic, and Caucasian cohorts. At the same time in work funded by the National MS society, we are testing a novel compound in a mouse model of MS we believe will reduce neuronal damage and also increase the myelin sheath that surrounds and protections nerve cells. We are also working on a project to evaluate the consequences of excessive alcohol consumption on the development of AD. We found that exposing brain ‘support’ cells (glial cells) to ethanol reduces their ability to clear amyloid plaques; we plan to extend those cell studies to a mouse model of AD. We have also been funded to carry out studies that may have particular importance to our active military as well as veteran population, namely studies on possible neurological damage caused by commonly used anti- coagulants (e.g.warfarin), and also more potent ‘superwarfarins’ that are used as rodenticides, but unfortunately have also been used in military situations. We are developing methods using FDA-approved drugs, we hope will prevent the toxic effects of these drugs as well as long term consequences.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Accelerating remyelination using lanthionine ketimine derivatives
  • 批准号:
    10708047
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2022
  • 负责人:
    Douglas L. Feinstein
  • 依托单位:
Optimization of Bile Sequestrants to Treat Superwarfarin Poisoning
  • 批准号:
    10707127
  • 项目类别:
  • 资助金额:
    $64.39万
  • 财政年份:
    2022
  • 负责人:
    Douglas L. Feinstein
  • 依托单位:
Accelerating remyelination using lanthionine ketimine derivatives
  • 批准号:
    10539555
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2022
  • 负责人:
    Douglas L. Feinstein
  • 依托单位:
Characterization of the oral microbiome of patients with Multiple Sclerosis
  • 批准号:
    10484039
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2022
  • 负责人:
    Douglas L. Feinstein
  • 依托单位:
海外基金